Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.

Schmiedel BJ, Nuebling T, Steinbacher J, Malinovska A, Wende CM, Azuma M, Schneider P, Grosse-Hovest L, Salih HR.

J Immunol. 2013 Jan 15;190(2):821-31. doi: 10.4049/jimmunol.1201792. Epub 2012 Dec 14.

2.

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR.

Blood. 2010 Apr 15;115(15):3058-69. doi: 10.1182/blood-2009-06-227934. Epub 2009 Dec 14. Erratum in: Blood. 2010 Dec 23;116(26):6152.

3.

RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.

Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, Schneider P, Jung G, Grosse-Hovest L, Salih HR.

Cancer Res. 2013 Jan 15;73(2):683-94. doi: 10.1158/0008-5472.CAN-12-2280. Epub 2012 Nov 8.

4.

Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.

Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR.

Cancer Res. 2009 Feb 1;69(3):1037-45. doi: 10.1158/0008-5472.CAN-08-2650. Epub 2009 Jan 20.

5.

Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).

Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ, Salih HR.

Leukemia. 2012 May;26(5):991-1000. doi: 10.1038/leu.2011.313. Epub 2011 Nov 8.

PMID:
22064350
6.

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.

Prostate. 2008 Jan 1;68(1):92-104.

7.

Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.

Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG, Yang DK, Lee WS, Kim HS, Rho J, Oh GT, Abel ED, Park WJ, Min JK, Kim J.

Cardiovasc Res. 2012 Apr 1;94(1):105-14. doi: 10.1093/cvr/cvs078. Epub 2012 Feb 1.

PMID:
22298642
8.

The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.

Shin M, Matsuo K, Tada T, Fukushima H, Furuta H, Ozeki S, Kadowaki T, Yamamoto K, Okamoto M, Jimi E.

Carcinogenesis. 2011 Nov;32(11):1634-40. doi: 10.1093/carcin/bgr198. Epub 2011 Sep 1.

PMID:
21890459
9.

Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.

Pelle DW, Ringler JW, Peacock JD, Kampfschulte K, Scholten DJ 2nd, Davis MM, Mitchell DS, Steensma MR.

Transl Res. 2014 Aug;164(2):139-48. doi: 10.1016/j.trsl.2014.03.005. Epub 2014 Mar 21.

PMID:
24726460
11.

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT.

Blood. 2007 Jan 1;109(1):323-30. Epub 2006 Aug 29.

12.

A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.

Lee JY, Park S, Kim DC, Yoon JH, Shin SH, Min WS, Kim HJ.

J Clin Immunol. 2013 May;33(4):826-37. doi: 10.1007/s10875-013-9877-2. Epub 2013 Feb 13.

PMID:
23404187
13.

RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.

Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM.

Circ Res. 2009 May 8;104(9):1041-8. doi: 10.1161/CIRCRESAHA.108.189001. Epub 2009 Mar 26.

14.

Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.

Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y.

J Pathol. 2009 Aug;218(4):530-9. doi: 10.1002/path.2567.

PMID:
19455604
15.

4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.

Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig K, Salih HR.

Eur J Immunol. 2012 Mar;42(3):737-48. doi: 10.1002/eji.201141920. Epub 2011 Dec 20.

16.
17.

The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.

Komuro H, Olee T, Kühn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M.

Arthritis Rheum. 2001 Dec;44(12):2768-76.

PMID:
11762937
18.
19.

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.

Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG.

Anticancer Res. 2013 Jan;33(1):199-206.

PMID:
23267146
20.

NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.

Wang Y, Chen C, Dong F, Ma S, Xu J, Gong Y, Cheng H, Zhou Y, Cheng T, Hao S.

Sci China Life Sci. 2015 Dec;58(12):1288-98. doi: 10.1007/s11427-015-4968-3. Epub 2015 Nov 20.

PMID:
26588911

Supplemental Content

Support Center